Phosphoramidate Peptidomimetic Inhibitors for PSMA Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer diagnosis and therapy using antibodies face challenges such as slow elimination from the blood, poor vascular permeability, and limited ability to bind to neighboring cell-surface sites, which restricts their effectiveness in targeting prostate-specific membrane antigen (PSMA) for prostate cancer detection and treatment.
Innovation Solution
Development of small molecules with high affinity and specificity to PSMA, derived from a central phosphoramidate core, which can be functionalized to deliver diagnostic or therapeutic agents directly to PSMA-expressing cells, offering efficient preparation and purification compared to antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are used to target PSMA for diagnostic and therapeutic purposes, then specific binding to PSMA is achieved, but slow elimination from blood and poor vascular permeability limit effectiveness
Solution Approach 1:
The patent changes the molecular size parameter from large antibodies to small molecule inhibitors, fundamentally altering pharmacokinetic properties including elimination rate and vascular permeability while maintaining target binding capability
Solution Approach 2:
The invention creates simplified molecular copies that replicate the target-binding function of antibodies without the structural complexity, using small molecules designed to mimic antibody-antigen interactions at the PSMA target site
2Reliability
If large antibodies are used to bind to cell-surface PSMA targets, then diagnostic and therapeutic delivery is achieved, but they present a barrier for subsequent binding of additional antibodies at neighboring sites
Solution Approach 1:
The patent segments the target binding function into multiple independent small molecule units that can simultaneously occupy multiple PSMA sites on the same cell or neighboring cells, unlike single large antibody molecules
Solution Approach 2:
The small molecule inhibitors are designed to bind with high affinity to PSMA targets while their smaller size allows excessive binding capacity across multiple sites, enabling both diagnostic and therapeutic functions to be achieved more effectively
3Reliability
If antibodies are used for PSMA targeting, then cell-surface target binding is achieved, but preparation and purification are time-consuming and costly
Solution Approach 1:
The patent employs small molecule inhibitors that are chemically synthesized rather than biologically produced, making them cheaper to manufacture and purify compared to antibodies, even if their functional lifespan in the body is shorter
Solution Approach 2:
The invention replaces the complex biological production and purification system required for antibodies with a chemical synthesis system for small molecules, fundamentally changing the manufacturing approach from biotechnological to chemical processes
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Compounds of the formula, A-L-B, wherein A is glutamate or a glutamate analog; L is a phosphoramidate or a phosphoramidate analog; and B is serine or a serine analog are described which are potent inhibitors of prostate-specific membrane antigen (PMSA). Such compounds are useful in treatment of prostate cancer; and when chemically attached to a fluorescent dye, can efficiently and selectively label prostate cancer cells for fluorescent imaging.